(ARGX) Argen-X - Ratings and Ratios

Exchange: BR • Country: Netherlands • Currency: EUR • Type: Common Stock • ISIN: NL0010832176

Therapies, Treatments, Medicines, Autoimmune, Diseases

ARGX EPS (Earnings per Share)

EPS (Earnings per Share) of ARGX over the last years for every Quarter: "2020-06": -4.64, "2020-09": -3.16, "2020-12": -6.6, "2021-03": -0.95, "2021-06": 0.99, "2021-09": -4.54, "2021-12": -8.04, "2022-03": -4.36, "2022-06": -7.78, "2022-09": -4.26, "2022-12": -4.62, "2023-03": -0.52, "2023-06": -2.03, "2023-09": -1.25, "2023-12": -2.65, "2024-03": -1.04, "2024-06": -0.51, "2024-09": 1.39, "2024-12": 11.78,

ARGX Revenue

Revenue of ARGX over the last years for every Quarter: 2020-06: 30.525349, 2020-09: 11.464286, 2020-12: 22.640838, 2021-03: 186.019406, 2021-06: 420.443972, 2021-09: 0.857, 2021-12: 26.039068, 2022-03: 23.412, 2022-06: 111.354833, 2022-09: 137.981, 2022-12: 302.906729, 2023-03: 219.14, 2023-06: 468.202506, 2023-09: 329.789, 2023-12: 686.305638, 2024-03: 401.001, 2024-06: 841.961923, 2024-09: 573.236, 2024-12: 1303.249599,

Description: ARGX Argen-X

Argen-X (BR:ARGX) is a commercial-stage biopharma company that develops therapies for treating autoimmune diseases. The company has a strong product pipeline, with VYGART and VYGART HYTRULO already approved for treating generalized myasthenia gravis (gMG), immune thrombocytopenia (ITP), and chronic inflammatory demyelinating polyneuropathy (CIDP).

The companys product pipeline includes efgartigimod, empasiprubart, and ARGX-119, which are being developed for various indications, including seronegative and ocular gMG, thyroid eye diseases, myositis, Sjögrens disease, lupus nephropathy, and amyotrophic lateral sclerosis. Argen-X also has a robust research and development program, with multiple candidates in various stages of development, including ARGX-109, ARGX-121, ARGX-213, and ARGX-118.

From a financial perspective, Argen-X has a market capitalization of approximately €28.98 billion, with a price-to-earnings ratio of 33.60 and a forward price-to-earnings ratio of 54.95. The companys return on equity is 24.42%, indicating a strong ability to generate profits from shareholder equity. Key performance indicators (KPIs) to watch include revenue growth, R&D expenses as a percentage of revenue, and the number of patients treated with VYGART and VYGART HYTRULO.

Argen-X has established strategic collaborations with multiple partners, including OncoVerity, LEO Pharma, Zai Lab, AbbVie, and Genmab, among others. These partnerships can help accelerate the development and commercialization of the companys products, potentially driving future growth and revenue. Investors should monitor the progress of these partnerships and the companys ability to execute on its development plans.

To further evaluate Argen-Xs potential, investors can analyze additional KPIs, such as the companys cash runway, the number of upcoming milestones, and the competitive landscape for its products. A thorough analysis of these factors can help investors make a more informed decision about the companys potential for future growth and returns.

Additional Sources for ARGX Stock

Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle

ARGX Stock Overview

Market Cap in USD 33,717m
Sector Healthcare
Industry Biotechnology
GiC Sub-Industry Biotechnology
IPO / Inception 2017-05-18

ARGX Stock Ratings

Growth Rating 60.3
Fundamental 63.5
Dividend Rating 0.0
Rel. Strength 31.2
Analysts -
Fair Price Momentum 483.91 EUR
Fair Price DCF -

ARGX Dividends

Currently no dividends paid

ARGX Growth Ratios

Growth Correlation 3m -78.1%
Growth Correlation 12m 16.4%
Growth Correlation 5y 90.4%
CAGR 5y 15.40%
CAGR/Max DD 5y 0.39
Sharpe Ratio 12m 1.03
Alpha 9.23
Beta 0.098
Volatility 32.95%
Current Volume 68.7k
Average Volume 20d 74.6k
Stop Loss 475.9 (-3%)
What is the price of ARGX shares?
As of July 19, 2025, the stock is trading at EUR 490.80 with a total of 68,657 shares traded.
Over the past week, the price has changed by +1.11%, over one month by +3.81%, over three months by -6.37% and over the past year by +15.92%.
Is Argen-X a good stock to buy?
Yes, based on ValueRay´s Fundamental Analyses, Argen-X (BR:ARGX) is currently (July 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 63.54 and therefor a positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ARGX is around 483.91 EUR . This means that ARGX is currently overvalued and has a potential downside of -1.4%.
Is ARGX a buy, sell or hold?
Argen-X has no consensus analysts rating.
What are the forecasts for ARGX share price target?
According to our own proprietary Forecast Model, ARGX Argen-X will be worth about 522.6 in July 2026. The stock is currently trading at 490.80. This means that the stock has a potential upside of +6.49%.
Issuer Target Up/Down from current
Wallstreet Target Price 666.3 35.7%
Analysts Target Price - -
ValueRay Target Price 522.6 6.5%